CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project aims to develop and validate imaging biomarkers for drug-induced lung disease. It focuses on translating these biomarkers into clinical tools that can predict outcomes and improve drug development processes.
1.Our consortium has broad, deep experience of drug development and imaging biomarker (IB) validation.
We are internationally recognized experts in transporter biology, animal models of lung injury, toxicology, DCEMRI, compartmental modeling, 1H&129Xe lung MR, and labeling of biologicals with PET and fluorescence tags, together with physicians who care for relevant patients.
We have an outstanding record of translating IBs: (a) into animals, (b) into man, (c) into tools which drug developers use…
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, MANCHESTER
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
France, DIJON
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Sweden, Goteborg
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
